Fibromyalgia

Fibromyalgia is a chronic, non-inflammatory disorder characterized by widespread musculoskeletal pain, fatigue, and cognitive dysfunction, affecting approximately 2-4% of the general population with a female-to-male ratio of 3-4:1. The condition typically manifests in middle-aged adults but can occur across all age groups and demographics. Fibromyalgia represents a syndrome of central sensitization with amplified pain processing rather than peripheral tissue pathology, making it a diagnosis of clinical recognition rather than structural abnormality. The condition significantly impairs quality of life, productivity, and healthcare utilization, accounting for substantial morbidity despite its non-fatal nature. Understanding fibromyalgia is essential for board examinations because it appears frequently in clinical vignettes and requires differentiation from inflammatory arthritides, making it a high-yield topic for Step 2 CK and clinical practice.

Fibromyalgia fundamentally represents a disorder of nociceptive processing and pain amplification at the central nervous system level, though the complete pathophysiology remains incompletely understood. Multiple interconnected mechanisms contribute to the clinical manifestations:

Central sensitization describes the state in which the nervous system becomes progressively more responsive to nociceptive input, resulting in increased pain sensitivity to normally noxious stimuli (hyperalgesia) and pain in response to normally non-noxious stimuli (allodynia). Functional neuroimaging studies, including fMRI and PET scanning, demonstrate that fibromyalgia patients exhibit enhanced activation in pain-processing brain regions (anterior cingulate cortex, anterior insula, prefrontal cortex) with reduced activation of pain-inhibitory networks. The dorsolateral prefrontal cortex, which normally exerts descending inhibitory control over pain, shows diminished activity in fibromyalgia patients. This altered central processing means that the same peripheral stimulus produces heightened pain perception compared to healthy controls—a fundamental distinction from inflammatory arthritis where peripheral tissue damage drives pain.

Cerebrospinal fluid (CSF) analysis in fibromyalgia patients reveals significantly elevated substance P (approximately 3-fold higher than controls), a neuropeptide that facilitates pain transmission in the dorsal horn of the spinal cord. Conversely, patients demonstrate reduced levels of serotonin and its precursor 5-hydroxytryptophan (5-HTP), contributing to both pain amplification and associated mood dysfunction. The monoamine hypothesis posits that deficiency in serotonin, norepinephrine, and dopamine—neurotransmitters crucial for descending pain inhibition—allows unopposed nociceptive signaling. Additionally, fibromyalgia involves dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, with abnormal cortisol secretion patterns (often reduced, particularly at awakening), impairing the body's capacity to modulate inflammatory responses and stress-induced pain amplification. This neuroendocrine dysfunction perpetuates the pain cycle and contributes to fatigue and mood disturbance.

Recent research demonstrates that activated microglia (brain resident immune cells) release pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-8 (IL-8), which sensitize nociceptors and enhance pain signaling. Although fibromyalgia is not a primary inflammatory condition (normal peripheral inflammatory markers), neuroinflammation in the central nervous system—particularly in pain-processing regions—contributes significantly to symptomatology. The elevation of pro-inflammatory cytokines in CSF correlates with pain severity. Additionally, glial cell-derived neurotrophic factor (GDNF) dysregulation impairs neuronal support and contributes to pain processing abnormalities. This neuroinflammatory process is distinct from peripheral inflammation, explaining why NSAIDs provide minimal benefit.

Twin studies demonstrate 50% heritability for fibromyalgia, supporting a genetic contribution. Several candidate genes have been implicated, including polymorphisms in the serotonin transporter gene (5-HTTLPR), catechol-O-methyltransferase (COMT) (which metabolizes dopamine and norepinephrine), and dopamine receptor D4 (DRD4) genes. A COMT variant resulting in reduced enzyme activity leads to higher dopamine levels but paradoxically increased pain sensitivity through altered reward system and pain modulation. Epigenetic modifications, including DNA methylation alterations affecting genes involved in pain processing and immune function, may be triggered by environmental stressors in genetically predisposed individuals. These genetic factors explain familial clustering of fibromyalgia and why only a subset of exposed individuals develops the condition.

Emerging evidence demonstrates that a subset of fibromyalgia patients (approximately 40-50%) exhibit small fiber neuropathy (SFN) on skin biopsy, characterized by reduced intraepidermal nerve fiber density. These small unmyelinated C fibers and Aδ fibers are crucial for nociception and temperature sensation. The reduced density or dysfunction of peripheral nociceptors may initiate central sensitization, establishing a feed-forward loop where altered peripheral input sustains central processing abnormalities. Additionally, wind-up phenomenon—wherein repeated C-fiber stimulation produces escalating pain responses—contributes to the temporal summation of pain in fibromyalgia.

Polysomnographic studies reveal that fibromyalgia patients demonstrate disrupted sleep architecture with intrusion of alpha waves (characteristic of wakefulness) into slow-wave sleep (stages 3-4), resulting in non-restorative sleep despite adequate sleep duration. This α-δ sleep abnormality prevents restorative deep sleep necessary for neuroendocrine repair, growth hormone secretion, and pain modulation. Chronic sleep deprivation amplifies pain perception through multiple mechanisms: reduced descending pain inhibition, upregulation of pro-inflammatory cytokines, impaired emotional regulation, and decreased pain threshold. Sleep disturbance may be both a cause and consequence of fibromyalgia, creating a vicious cycle.

Fibromyalgia involves autonomic imbalance with increased sympathetic tone and reduced parasympathetic tone, evidenced by abnormal heart rate variability, impaired blood pressure regulation, and altered catecholamine responses. This autonomic dysregulation contributes to tachycardia, blood pressure variability, reduced exercise tolerance, and amplified stress reactivity, perpetuating pain and fatigue.

While fibromyalgia is primarily a neurobiological syndrome rather than a disease with a specific causative pathogen or defect, multiple risk factors and predisposing conditions contribute to its development:

As discussed in pathophysiology, fibromyalgia demonstrates 50% heritability with multiple polymorphisms in pain-processing and neurotransmitter genes. First-degree relatives of fibromyalgia patients have an 8-fold increased risk of developing the condition compared to the general population. This genetic foundation explains why fibromyalgia clusters in families and why environmental triggers alone cannot account for disease development.

Childhood trauma, including physical or sexual abuse, and significant adult stressors (loss, divorce, serious illness) precede fibromyalgia onset in a substantial proportion of patients. Post-traumatic stress disorder (PTSD) and severe anxiety disorders significantly increase fibromyalgia risk, likely through sustained HPA axis dysregulation and alterations in pain processing. The mechanism involves sensitization of the fear-conditioning system and amplified threat perception, creating chronic hypervigilance and pain amplification. This association does not imply psychological origin but rather demonstrates how psychological stressors can trigger neurobiological changes in predisposed individuals.

Fibromyalgia frequently develops or worsens following significant physical trauma, including motor vehicle accidents, surgical procedures, severe infections, or injuries resulting in prolonged pain. Post-traumatic fibromyalgia emerges in approximately 10-15% of patients following whiplash injury or significant trauma. The mechanism involves central sensitization triggered by prolonged nociceptive input, wherein the sustained pain signal from acute injury initiates maladaptive neuroplasticity and altered pain processing that persists after tissue healing. Viral infections, particularly Epstein-Barr virus (EBV) and cytomegalovirus (CMV), have been temporally associated with fibromyalgia onset in some patients, though causality remains unproven. Lyme disease, though controversial, has been implicated in fibromyalgia development in endemic regions, though distinguishing true causation from coincidental association remains challenging.

The 3-4:1 female predominance suggests significant hormonal contributions. Fibromyalgia often coincides with major reproductive transitions: menarche, oral contraceptive use, pregnancy, and menopause. Estrogen dysregulation, progesterone deficiency, and abnormal growth hormone secretion (which is estrogen-responsive) likely contribute. Pregnancy occasionally ameliorates fibromyalgia symptoms, possibly through immune modulation and altered pain processing, while postpartum worsening is common. Hormone replacement therapy effects are variable and patient-specific.

Depression, anxiety disorders, and somatization disorders frequently coexist with fibromyalgia and may represent both risk factors and consequences of the condition. The shared neurobiological substrate—including monoamine dysfunction and HPA axis dysregulation—underlies both pain amplification and mood disturbance. Patients with pre-existing major depression have increased fibromyalgia risk, and fibromyalgia development typically worsens pre-existing psychiatric conditions.

Fibromyalgia frequently develops in the context of established rheumatic diseases, particularly systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's syndrome. This "secondary fibromyalgia" represents superimposed central sensitization in patients with underlying inflammatory arthritis. The distinction matters clinically: secondary fibromyalgia requires treatment of both the underlying inflammatory condition and the pain amplification syndrome. Chronic pain conditions including chronic fatigue syndrome (CFS/ME), irritable bowel syndrome (IBS), and migraine frequently co-occur with fibromyalgia, suggesting shared central sensitization mechanisms and common pathophysiological pathways. Hypothyroidism, though not directly causing fibromyalgia, predisposes to the condition through metabolic and immune effects.

Certain medications, particularly statins (which can cause myalgia) and beta-blockers (which may impair pain modulation), have been associated with fibromyalgia-like symptoms in susceptible individuals. Environmental toxin exposure, including heavy metals and organic solvents, may trigger fibromyalgia in genetically predisposed individuals, though evidence remains limited. Sedentary lifestyle and physical deconditioning perpetuate fibromyalgia through reduced endorphin production, increased pain perception, and muscle atrophy.

Fibromyalgia presents as a constellation of symptoms reflecting central sensitization and autonomic dysfunction:

By definition, patients experience pain persisting for >3 months affecting bilateral upper extremities, bilateral lower extremities, and axial skeleton (neck, chest, or lower back). The pain is typically described as aching, burning, throbbing, or sharp and is characteristically non-dermatomal and non-anatomical in distribution, distinguishing it from neuropathic pain following specific nerve territories. Pain severity typically fluctuates day-to-day and even hour-to-hour, often worsened by stress, physical exertion, and sleep deprivation. Importantly, the pain is disproportionate to objective findings on examination and imaging, a crucial distinction from inflammatory arthritis. Patients may experience regional pain patterns that evolve over time. Some patients report that pain is worst upon awakening, reflecting non-restorative sleep, while others note progressive worsening throughout the day with activity. Pain may have discrete trigger points (discussed below) or may be more diffuse.

Profound fatigue affects 75-90% of fibromyalgia patients and frequently equals or exceeds pain in symptom burden. The fatigue is characteristically not relieved by rest and worsens with exertion—a pattern termed post-exertional malaise (PEM) when excessive physical activity triggers disproportionate fatigue lasting days. This distinguishes fibromyalgia fatigue from simple deconditioning. Sleep disturbance is nearly universal, with patients reporting difficulty initiating sleep, frequent nocturnal awakenings, and non-restorative quality despite apparently adequate duration. Morning unrefreshedness is characteristic. Patients often report paradoxical tiredness despite attempting sleep.

Approximately 50-80% of patients experience cognitive impairment colloquially termed "fibrofog," characterized by difficulties with concentration, memory (particularly working memory and short-term recall), word-finding, and executive function. Patients describe feeling mentally "foggy" or "cloudy" and struggle with complex tasks requiring sustained attention. Testing typically reveals normal cognition on formal neuropsychological testing, distinguishing fibrofog from dementia or delirium. The mechanism involves altered central pain processing that competes for cognitive resources, combined with sleep deprivation effects and monoamine dysfunction. Fibrofog significantly impacts work performance and quality of life.

Patients frequently report feeling "cold all the time" despite normal ambient temperature, or conversely, excessive sweating, reflecting autonomic dysregulation. Night sweats occur in approximately 25% of patients, sometimes severe enough to soak bedding, yet without fever (distinguishing from occult infection or malignancy). Patients may experience dizziness, lightheadedness, or presyncope from orthostatic intolerance and blood pressure dysregulation. Palpitations and chest discomfort are common, causing patients to fear cardiac pathology, though cardiac evaluation is typically negative. Flushing and facial redness may occur. These autonomic symptoms reflect sympathetic overactivity and parasympathetic insufficiency.

Depression occurs in 30-50% of fibromyalgia patients (or vice versa—depression precedes fibromyalgia in some), manifesting as depressed mood, anhedonia, loss of interest, and hopelessness. Anxiety disorders, including generalized anxiety disorder (GAD), social anxiety, and panic disorder, occur in 20-40% of patients. These psychiatric comorbidities share the underlying monoamine dysfunction and HPA axis dysregulation and significantly worsen pain perception and fatigue. The relationship is bidirectional: pain amplification increases psychological distress, which further amplifies pain.

Irritable bowel syndrome (IBS) occurs in 40-60% of fibromyalgia patients, manifesting as abdominal pain, bloating, diarrhea alternating with constipation, and dysmotility. This high co-occurrence reflects shared mechanisms of visceral hypersensitivity and altered gut motility. Tension-type headaches and migraines occur in approximately 40% of patients. Temporomandibular joint (TMJ) dysfunction with jaw pain, clicking, and limited opening is common. Restless leg syndrome affects up to 30% of patients. Patients may report widespread paresthesias (numbness, tingling) in extremities, though objective sensory testing is normal—a distinction from true neuropathy. Dry eyes and dry mouth (sicca symptoms) occur frequently, sometimes prompting evaluation for Sjögren's syndrome (though specific antibodies are typically absent in primary fibromyalgia).

Tender Points and Tender Point Count: The most characteristic physical finding is tenderness at specific anatomical sites out of proportion to findings in controls. The American College of Rheumatology (ACR) 1990 and 2016 diagnostic criteria identified 18 tender points (9 paired bilateral locations): occiput (suboccipital muscle insertions), lower cervical (C5-C7 interspinous ligament), trapezius (midpoint upper border), supraspinatus (above scapular spine at medial border), second rib, lateral epicondyle, gluteus maximus (upper outer quadrant), greater trochanter, and knee (medial fat pad). Tenderness is elicited by applying 4 kg/cm² pressure (approximately the weight of a hand pressing until the examiner's thumbnail blanches). Historically, diagnosis required ≥11 of 18 tender points, though this criterion is less central in 2016

Fibromyalgia is a clinical diagnosis of inclusion — it is made by meeting criteria, not by exhausting every test — and can coexist with rheumatic disease (secondary fibromyalgia).

Red flags mandating a different workup: fever, weight loss, objective joint swelling, proximal weakness with high CK, new focal neurologic deficit, or age >50 with shoulder/hip girdle stiffness and high ESR (polymyalgia rheumatica).

There is no emergency stabilization phase; the acute task is to make the diagnosis explicitly, name it to the patient, and screen for depression and suicidality, since validation itself reduces healthcare utilization. US practice largely follows the EULAR 2016 revised recommendations for the management of fibromyalgia, which place non-pharmacologic therapy first.

Escalation: combine an evening TCA/gabapentinoid with a daytime SNRI; add multimodal rehabilitation, tai chi/yoga, or mindfulness-based stress reduction. Tramadol is a weak-evidence rescue only, with serotonin-syndrome risk alongside an SNRI.